EUVIMEDEUVIMED entdecken
MetaanalyseValidierungsstudieNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: Significant role of alpha-fetoprotein

Dongman Yu, Yeongseok Hwang, Jin-Sung Ju, Subin Heo, Seon-Ok Kim, Sang Hyun Choi, Gi-Won Song, Jihyun An, Ju Hyun Shim

Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 751-771

DOI: 10.3350/cmh.2025.0986 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Dongman Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Transplantation, alpha-Fetoproteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Asan Cancer Institute of Asan Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Various expanded criteria (EC) for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) have been proposed to avoid the narrow nature of the Milan criteria (MC). To investigate which EC predicts more favorable outcomes in terms of overall survival (OS) and recurrence-free survival (RFS), we conducted a network meta-analysis (NMA).

Methods

A database search was conducted on PubMed, Embase, and the Cochrane Library, to identify studies comparing OS and RFS between patients within the MC and those exceeding the MC but within the EC. Hazard ratios (HRs) were pooled using a random-effects NMA and validated in an in-house cohort of 1,008 LT recipients.

Results

Among 22,466 articles identified, 35 studies with 45 pairwise comparisons were included in the NMA along with 8 different EC. The University of California San Francisco (HR, 1.43; 95% CI, 1.19–1.71), Up-to-Seven (HR, 1.50; 95% CI, 1.15–1.97), and Hangzhou criteria (HR, 1.69; 95% CI, 1.11–2.57) showed inferior OS to the MC. The MC ranked highest for both OS and RFS, followed by Metroticket 2.0 for OS and the Asan criteria for RFS. In the validation cohort, both Metroticket 2.0 and AFP model yielded more favorable HCC-specific mortality than other EC.

Conclusions

Several EC, of which those of Metroticket 2.0 were the best, yielded comparable outcomes to the MC. AFP-based EC such as Metroticket 2.0 and AFP model appeared to be useful in both the NMA and the validation cohort, suggesting a potential role in identifying selected low-risk patients beyond the MC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver Transplantationalpha-FetoproteinsHumansProportional Hazards ModelsDisease-Free SurvivalPrognosis

Stichwörter der Autor:innen

Carcinoma, hepatocellularLiver transplantationMeta-analysisPrognosis

Substanzen

alpha-Fetoproteins

Autor:innen und Institutionen

  • Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Biostatistics and Clinical Epidemiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Gastroenterology and Hepatology, Hanyang University College of Medicine, Guri, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Asan Cancer Institute of Asan Medical Center
  • Korean Liver Cancer Association

Zitieren

APA

Yu, D., Hwang, Y., Ju, J. S., Heo, S., Kim, S. O., Choi, S. H., Song, G. W., An, J., & Shim, J. H. (2026). Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: Significant role of alpha-fetoprotein. Clinical and Molecular Hepatology, 32(2), 751-771. https://doi.org/10.3350/cmh.2025.0986

Vancouver

Yu D, Hwang Y, Ju JS, Heo S, Kim SO, Choi SH, et al. Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: Significant role of alpha-fetoprotein. Clinical and Molecular Hepatology. 2026;32(2):751-771. doi:10.3350/cmh.2025.0986

BibTeX
@article{Yu2026,
  author = {Yu, Dongman and Hwang, Yeongseok and Ju, Jin-Sung and Heo, Subin and Kim, Seon-Ok and Choi, Sang Hyun and Song, Gi-Won and An, Jihyun and Shim, Ju Hyun},
  title = {Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: Significant role of alpha-fetoprotein},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {751--771},
  doi = {10.3350/cmh.2025.0986}
}
Kostenlos starten →